Clinical Trials Browser

Phase 2 × INDUSTRY × sitravatinib × Clear all

NCT05461794 2025-06-13

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Phase 2 Terminated

96 enrolled 17 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02954991 2024-04-22

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Phase 2 Terminated

161 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT03680521 2023-10-04

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

Phase 2 Completed

25 enrolled 22 charts

Carcinoma, Renal Cell

NCT03606174 2023-08-24

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

260 enrolled 28 charts

Carcinoma, Transitional Cell